Multigene Copy Number Alteration Risk Score Biomarker-Based Enrichment Study Designs in Metastatic Castrate-Resistant Prostate Cancer

Overview

Journal JCO Precis Oncol

Specialty Oncology

Date 2024 Dec 3

PMID 39626157

Authors

Yeonjung Jo

Jonathan J Chipman

Benjamin Haaland

Tom Greene

Manish Kohli

Affiliations

Soon will be listed here.

Abstract

Purpose: A composite multigene risk score derived from tumor-biology alterations specific to metastatic castrate-resistant prostate cancer (mCRPC) state was evaluated as a classifier to design biomarker-based enrichment clinical trials.

Methods: A plasma cell-free DNA copy number alteration risk score based on alterations in 24 genes was simulated to develop a biomarker classifier-based clinical trial design enriched for high-risk patients to detect a survival advantage of a novel treatment (hazard ratio of 0.70 with 80% power). We determined the design trade-offs between the number of patients screened and enrolled when varying the type of patients to enrich and the extent of enrichment needed.

Results: For a 2-year overall survival end point in mCRPC state, fully enriching patients with mCRPC having a high-risk score of 3 or more (the 95th percentile of a range of risk scores in patients with mCRPC) was determined to require screening to a maximum of 4,149 patients to enroll 259 patients for the targeted effect size. A nonenriched trial was determined to require enrolling 689 patients to be equivalently powered. We identified a pragmatic alternative, which is to enrich patients with mCRPC with a risk score of 1 or more (the 67th percentile) and an enrichment fraction of 0.25. This would require screening 658 patients to enroll 584 patients, and it maximizes the ability to detect a difference in treatment effect by risk score.

Conclusion: A plasma multi-CNA risk score classifier can feasibly be leveraged to design an enrichment trial in mCRPC. Enriching 25% of patients screened with a risk score >1 was observed to be optimal for obtaining an adequately powered, biomarker-based mCRPC-enriched clinical trial.

References

Ryan C, Smith M, de Bono J, Molina A, Logothetis C, de Souza P . Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2012; 368(2):138-48. PMC: 3683570. DOI: 10.1056/NEJMoa1209096. View

Shaw A, Ou S, Bang Y, Camidge D, Solomon B, Salgia R . Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014; 371(21):1963-71. PMC: 4264527. DOI: 10.1056/NEJMoa1406766. View

Kalinsky K, Barlow W, Gralow J, Meric-Bernstam F, Albain K, Hayes D . 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. N Engl J Med. 2021; 385(25):2336-2347. PMC: 9096864. DOI: 10.1056/NEJMoa2108873. View

Park K, Haura E, Leighl N, Mitchell P, Shu C, Girard N . Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. J Clin Oncol. 2021; 39(30):3391-3402. PMC: 8791812. DOI: 10.1200/JCO.21.00662. View

Cardoso F, Vant Veer L, Bogaerts J, Slaets L, Viale G, Delaloge S . 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med. 2016; 375(8):717-29. DOI: 10.1056/NEJMoa1602253. View

Beer T, Tombal B . Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014; 371(18):1755-6. DOI: 10.1056/NEJMc1410239. View

Siegel R, Giaquinto A, Jemal A . Cancer statistics, 2024. CA Cancer J Clin. 2024; 74(1):12-49. DOI: 10.3322/caac.21820. View

Sicotte H, Kalari K, Qin S, Dehm S, Bhargava V, Gormley M . Molecular Profile Changes in Patients with Castrate-Resistant Prostate Cancer Pre- and Post-Abiraterone/Prednisone Treatment. Mol Cancer Res. 2022; 20(12):1739-1750. PMC: 9716248. DOI: 10.1158/1541-7786.MCR-22-0099. View

Mok T, Wu Y, Ahn M, Garassino M, Kim H, Ramalingam S . Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2016; 376(7):629-640. PMC: 6762027. DOI: 10.1056/NEJMoa1612674. View

10.

Iacovelli R, Ciccarese C, Schinzari G, Rossi E, Maiorano B, Astore S . Biomarkers of response to advanced prostate cancer therapy. Expert Rev Mol Diagn. 2020; 20(2):195-205. DOI: 10.1080/14737159.2020.1707669. View

11.

Scher H, Halabi S, Tannock I, Morris M, Sternberg C, Carducci M . Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008; 26(7):1148-59. PMC: 4010133. DOI: 10.1200/JCO.2007.12.4487. View

12.

Dummer R, Ascierto P, Gogas H, Arance A, Mandala M, Liszkay G . Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018; 19(5):603-615. DOI: 10.1016/S1470-2045(18)30142-6. View

13.

Sparano J, Gray R, Ravdin P, Makower D, Pritchard K, Albain K . Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. N Engl J Med. 2019; 380(25):2395-2405. PMC: 6709671. DOI: 10.1056/NEJMoa1904819. View

14.

Fizazi K, Azad A, Matsubara N, Carles J, Fay A, De Giorgi U . First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nat Med. 2023; 30(1):257-264. PMC: 10803259. DOI: 10.1038/s41591-023-02704-x. View

15.

Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S . Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020; 383(24):2345-2357. DOI: 10.1056/NEJMoa2022485. View

16.

Simon R . The use of genomics in clinical trial design. Clin Cancer Res. 2008; 14(19):5984-93. DOI: 10.1158/1078-0432.CCR-07-4531. View

17.

Dehm S, Hillman D, Sicotte H, Tan W, Gormley M, Bhargava V . A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisone. Ann Oncol. 2017; 29(2):352-360. PMC: 6304474. DOI: 10.1093/annonc/mdx689. View

18.

Robert C, Grob J, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E . Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. N Engl J Med. 2019; 381(7):626-636. DOI: 10.1056/NEJMoa1904059. View

19.

Skoulidis F, Li B, Dy G, Price T, Falchook G, Wolf J . Sotorasib for Lung Cancers with p.G12C Mutation. N Engl J Med. 2021; 384(25):2371-2381. PMC: 9116274. DOI: 10.1056/NEJMoa2103695. View

20.

Wu Q, Qian W, Sun X, Jiang S . Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. J Hematol Oncol. 2022; 15(1):143. PMC: 9548212. DOI: 10.1186/s13045-022-01362-9. View